| Date Checked | 2026-06-19 21:34:18 |
|---|---|
| Graham Number | (PB)nan vs (PE)70.85 |
| Over / Under Value Percentage | 0.00% vs nan% |
| Dividend Yield | 2.97% |
| Dividend Date | 2026-05-15 |
| Symbol | ABBV |
| AssetType | Common Stock |
| Name | AbbVie Inc |
| Description | AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. |
| CIK | 1551152 |
| Exchange | NYSE |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | DRUG MANUFACTURERS - GENERAL |
| Address | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, UNITED STATES, 60064-6400 |
| OfficialSite | https://www.abbvie.com |
| FiscalYearEnd | December |
| LatestQuarter | 2026-03-31 |
| MarketCapitalization | 394118496000 |
| EBITDA | 29915001000 |
| PERatio | 109.89 |
| PEGRatio | 0.62 |
| BookValue | -3.767 |
| DividendPerShare | 6.74 |
| EPS | 2.03 |
| RevenuePerShareTTM | 35.5 |
| ProfitMargin | 0.0579 |
| OperatingMarginTTM | 0.322 |
| ReturnOnAssetsTTM | 0.1 |
| ReturnOnEquityTTM | 0.623 |
| RevenueTTM | 62819000000 |
| GrossProfitTTM | 45246001000 |
| DilutedEPSTTM | 2.03 |
| QuarterlyEarningsGrowthYOY | -0.462 |
| QuarterlyRevenueGrowthYOY | 0.124 |
| AnalystTargetPrice | 253.55 |
| AnalystRatingStrongBuy | 8 |
| AnalystRatingBuy | 16 |
| AnalystRatingHold | 8 |
| AnalystRatingSell | 0 |
| AnalystRatingStrongSell | 0 |
| TrailingPE | 109.89 |
| ForwardPE | 15.77 |
| PriceToSalesRatioTTM | 6.27 |
| PriceToBookRatio | 50.46 |
| EVToRevenue | 7.34 |
| EVToEBITDA | 27.24 |
| Beta | 0.309 |
| 52WeekHigh | 239.13 |
| 52WeekLow | 176.0 |
| 50DayMovingAverage | 209.85 |
| 200DayMovingAverage | 220.02 |
| SharesOutstanding | 1766793000 |
| SharesFloat | 1763648000 |
| PercentInsiders | 0.112 |
| PercentInstitutions | 76.909 |
| ExDividendDate | 2026-04-15 |
| naga | 1 |
| etoro | 1 |
| dateChecked | 2026-06-19 21:34:18 |
| fresh | 1 |